Company: Cipla Ltd. Category: Result Analysis

Cipla revenue grew by 11.7% YoY to Rs39.4bn (vs. estimates of Rs41bn) led by growth in domestic (22% YoY), South Africa (+23.2% YoY) and API biz (54% YoY).
Aug. 10, 2018, 10:26 a.m.

Drug major Cipla yesterday posted a 10 per cent increase in its consolidated net profit to Rs 451 crore for the first quarter ended June 30, driven by robust sales across various markets.
Aug. 9, 2018, 11:22 a.m.

Cipla had reported a net profit of Rs 408.8 crore for the corresponding quarter a year ago.
Aug. 9, 2018, 10:42 a.m.

Cipla’s 1QFY19 revenues (Rs39,390mn) and net earnings (Rs4,510mn) were above consensus estimates led by an one-time extraordinary contingent payment of Rs 850mn (Chase Pharma Divestment) reported as other income.
Aug. 9, 2018, 10:22 a.m.

Cipla’s adj Sales, adj. EBITDA and PAT of Rs38.5bn, Rs6.3bn and Rs4.5bn were below our estimates by 7%, 21% and 3% respectively.
Aug. 8, 2018, 10:40 a.m.

Cipla: 4QFY18 Result Update
May 23, 2018, 2:14 p.m.

Cipla : 4QFY18 Result Update
May 23, 2018, 2:10 p.m.

EBITDA and adj. PAT of Rs34.9bn, Rs3.5bn and Rs2.3bn and way below our estimates by 6%, 51% and 25% respectively.
May 23, 2018, 12:10 p.m.

Watch: Cipla posts Q4 profit of Rs 179 crore
May 22, 2018, 5:07 p.m.

Net Sales and PAT of the company are expected to grow at a CAGR of 8% and 6% over 2016 to 2019E respectively.Hence, we say that, we are Overweight in this particular scrip for Medium to Long term investment.
April 18, 2018, 1:43 p.m.